Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Neurocrine Biosciences Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $30.76, while Neurocrine Biosciences Inc trades at $155.85 (market cap $15.77B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | NBIX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $573.00 | $185.50 |
52-Week Low | $14.60 | $123.10 |
Market Cap | — | $15.77B |
Enterprise Value | — | $15.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $33.31, down 8.64% today, with technical indicators showing a bullish trend supported by moving averages. The ETF recently underwent a 10:1 reverse stock split and declared a $0.29 dividend payable in August 2026. Recent news highlights significant trading activity as investors seek leveraged exposure to MicroStrategy amid Bitcoin volatility, though the fund has experienced substantial value erosion over the past year.
The outlook remains volatile given MSTU's leveraged structure, which compounds daily moves. While technical momentum appears positive, fundamental risks include the amplified exposure to MicroStrategy's performance and crypto market swings. Investors should weigh the potential for rapid gains against the documented risk of significant value erosion in leveraged products.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
